Alexandra Glucksmann, Ph.D. - President and CEO Cedilla Therapeutics,

She is a veteran biopharma executive and experienced scientist who most recently served as founder and chief operating officer of the gene editing company Editas Medicine, Inc.

Alexandra previously served as senior vice president of research and development at Cerulean Pharma, which she also joined at its founding. Sandra was a founding scientist at Millennium Pharmaceuticals, where she spent 13 years, taking on a series of senior roles on the science team before moving into an executive position with responsibility for strategic program management and operations. 

Sandra serves on the boards of directors of gene therapy company REGENXBIO and Scenic Biotech. She has also chaired the Boston-based WEST - Women in the Enterprise of Science and Technology for most of the past 13 years.